- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03884413
FErtility, PrEgnancy, contRaceptIon After Breast Cancer in France (FEERIC)
FErtility, PrEgnancy, contRaceptIon After Breast Cancer in France: the FEERIC Study
Studieoversikt
Detaljert beskrivelse
Breast cancer is the most common cancer among women. With the increase of the survival rates, a growing attention is paid to the side effects of the treatments, particularly chemotherapy-induced infertility.
The FEERIC study will give insights into spontaneous fertility outcomes following breast cancer in comparison with a control cohort and will provide data to help patients counselling towards spontaneous fertility rates following breast cancer. It will also provide data on contraceptive prevalence and unintended pregnancy rates in French breast cancer survivors. Reasons for unmet need for family planning will be deciphered, in order to point out pitfalls (lack of patient's information or orientation/ignorance of contraception methods available/topic insufficiently or not discussed with the physician/ lack of family planning offer etc…); and target the appropriate actions to lead (oncologist and oncology nurses education/ dedicated consultations in breast cancer centers/etc…).
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiesteder
-
-
-
Paris, Frankrike
- Rekruttering
- Seintinelles.Com
-
Ta kontakt med:
- Laura SABLONE
- Telefonnummer: 33 1 06.07.44.74.36
- E-post: laura.sablone@seintinelles.com
-
Hovedetterforsker:
- Fabien REYAL, MD
-
Hovedetterforsker:
- Charles CHAPRON, Pr
-
Hovedetterforsker:
- Marc ESPIE, MD
-
Hovedetterforsker:
- Isabelle RAY-COQUARD, Pr
-
Hovedetterforsker:
- Claire SENECHAL, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- females aged from 18 to 43 at inclusion
- previous diagnosis of breast cancer and time from diagnosis comprised between one and five years or women free from breast cancer or other malignancy (healthy volunteers) .
Exclusion Criteria:
- hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy
- healthy volonteer with history of malignant disease.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
Breast cancer survivors
Study of spontaneous fertility outcomes following breast cancer history
|
Longitudinal observational study.
Collection of health data using self-administered questionnaires online.
|
Control group
Study of spontaneous fertility outcomes in healthy volonteers population
|
Longitudinal observational study.
Collection of health data using self-administered questionnaires online.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Spontaneous pregnancies between cases and controls
Tidsramme: 3 years
|
Odds ratio between the spontaneous pregnancies between cases and controls, for women with a desire to become pregnant and trying to get pregnant.
|
3 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Time to spontaneous pregnancy
Tidsramme: 3 years
|
Time to spontaneous pregnancy after breast cancer diagnosis, for women with a desire to become pregnant and trying to get pregnant.
|
3 years
|
Contraceptive prevalence
Tidsramme: 3 years
|
Contraceptive use, defined as the percentage of women reporting use of a contraceptive method.
|
3 years
|
Rate of women considered with risk of unintended pregnancy
Tidsramme: 3 years
|
An unwanted pregnancy is defined as unwanted at the time of conception.
Women are classified as at risk of unwanted pregnancy if they report having had unprotected sex without a desire to become pregnant in the previous four months.
|
3 years
|
Percentage of live births obtained by medically assisted procreation procedures
Tidsramme: 3 years
|
Percentages live births obtained by ARTs procédures, that include in vitro fertilization (IVF) and embryo transfer (ET), intracytoplasmic sperm injection (ICSI) and ovarian stimulation with exogenous gonadotropins.
|
3 years
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Anne-Sophie HAMY-PETIT, MD, Institut Curie
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IC 2016-07
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Brystkreft kvinne
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbeidspartnereFullførtThe Clinical Application Guide of Conebeam Breast CTKina
-
Novartis PharmaceuticalsFullførtMetastatisk brystkreft (MBC) | Locally Advance Breast Cancer (LABC)Storbritannia, Spania
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkjentHR-positiv, HER2-negativ og PIK3CA Mutation Advanced Breast CancerKina
-
Emory UniversityNational Cancer Institute (NCI)TilbaketrukketPrognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i hjernen | Metastatisk brystkarsinom | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeAnatomisk stadium IV brystkreft AJCC v8 | Prognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i beinet | Metastatisk malign neoplasma i lymfeknutene | Metastatisk malign neoplasma i leveren | Metastatisk brystkarsinom | Metastatisk malign neoplasma i lungen | Metastatisk malign neoplasma... og andre forholdForente stater, Canada, Saudi-Arabia, Korea, Republikken